Community/Retail

Individuals who reported zero or fewer live births and those who reported many live births had markers of quicker aging than those who reported 3 or 4 births.

Distribution of the first 2.9 million doses of the COVID--19 vaccine jointly developed by Pfizer and BioNTech are expected to begin within hours of the FDA’s decision.

A member of the FDA’s expert advisory committee who voted in favor of Pfizer and BioNTech’s COVID-19 vaccine said that distribution of the first vaccines to high priority populations in the United States could begin as early as Monday.

Genetic predisposition is only part of the pre-eclampsia risk.

Medication nonadherence results in greater health care spending and poorer patient health outcomes.

There are compelling reasons to use sodium-glucose cotransporter-2 (SGLT2) inhibitors for the treatment of type 2 diabetes, according to a session at the 2020 ASHP Midyear Clinical Meeting and Exhibition.

Paracelsus referred to the drug as the “stone of immortality,” which may have been the impetus for his fine-tuning it further. Later, Thomas Sydenham created his own version in the 1600s with the important addition of alcohol.

The objective of the study was to increase awareness among pharmacists about products for which unfounded claims have been made regarding prevention of severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) infections.

Supreme Court decision establishes that states do have the right to regulate pharmacy benefit managers in managed care organizations.

According to investigators, most medications should be stored at room temperature, between 68 and 77 degrees Fahrenheit.

Variability in prescrption handoffs might make the difference between a patient who is adherent or not.

Until COVID-19 vaccines are widely available, Anthony Fauci, MD, said the importance of public health measures cannot be understated.

Specifically, in rural settings, growing primary care provider shortages impact patient access to care.

If current drug pricing trends continue, cost-related non-adherence to therapy will result in the premature deaths of 112,000 Medicare beneficiaries per year.

The tau protein can help identify Alzheimer disease before cognitive decline begins.

Grief can affect an organization as well as an individual; however, there are management strategies that can be used for addressing these issues.

Accurate blood pressure measurement is crucial to diagnose hypertension and guide treatment.

Acquired hemophilia A is a rare bleeding disorder caused by autoantibodies that inhibit coagulation factor VIII (FVIII), and the disorder is understudied given its rarity and the lack of randomized prospective trials to guide therapy.

Suzanne Trudel, MD, MSC, FRCPC, of the University of Toronto and the Princess Margaret Cancer Centre in Toronto, discusses closing thoughts on the results of the study and its implications for future treatment options for patients with relapsed/refractory multiple myeloma.

Suzanne Trudel, MD, MSC, FRCPC, of the University of Toronto and the Princess Margaret Cancer Centre in Toronto, discusses what the implications of the high rate of dose holds that occurred in the study were, and whether there any plans to address this concern in the future.

Hagop Kantarjian, MD, of the University of Texas MD Anderson Cancer Center, discusses what his team’s plans are for the evaluation of ponatinib during the remaining portion of the OPTIC trial, which is currently ongoing.

Suzanne Trudel, MD, MSC, FRCPC, of the University of Toronto and the Princess Margaret Cancer Centre in Toronto, discusses whether the treatment emergent adverse events (AEs) were consistent with the known safety profiles for belantamab mafodotin and pomalidomide.

Suzanne Trudel, MD, MSC, FRCPC, of the University of Toronto and the Princess Margaret Cancer Centre in Toronto, discusses common adverse events (AEs) observed in patients with relapsed/refractory multiple myeloma following treatment with belantamab mafodotin in combination with pomalidomide and dexamethasone.

Hagop Kantarjian, MD, of the University of Texas MD Anderson Cancer Center, discusses what the interim analysis of the OPTIC trial demonstrated in terms of the safety and arterial occlusive events profiles with response-based ponatinib dosing regimens.

Suzanne Trudel, MD, MSC, FRCPC, of the University of Toronto and the Princess Margaret Cancer Centre in Toronto, discusses the common prior therapies for patients with relapsed/refractory multiple myeloma who were enrolled in the ALGONQUIN trial.

Hagop Kantarjian, MD, of the University of Texas MD Anderson Cancer Center, discusses what the PACE trial was able to demonstrate in regard to patient response to ponatinib for patients with resistant and intolerant chronic-phase CML with substantial prior second-generation treatment.

Suzanne Trudel, MD, MSC, FRCPC, of the University of Toronto and the Princess Margaret Cancer Centre in Toronto, discusses the dose limiting toxicities observed among patients with relapsed/refractory multiple myeloma following treatment with belantamab mafodotin in combination with pomalidomide and dexamethasone.

Suzanne Trudel, MD, MSC, FRCPC, of the University of Toronto and the Princess Margaret Cancer Centre in Toronto, discusses what belantamab mafodotin and pomalidomide are, and how they work together to treat relapsed/refractory multiple myeloma.